Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

845 results about "Neural stem cell" patented technology

Neural stem cells (NSCs) are self-renewing, multipotent cells that firstly generate the radial glial progenitor cells that generate the neurons and glia of the nervous system of all animals during embryonic development. Some neural progenitor stem cells persist in highly restricted regions in the adult vertebrate brain and continue to produce neurons throughout life.

Methods of making conditioned cell culture medium compositions

Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and / or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, formulated with a salve or ointment for topical applications, or, for example, made into or added to surgical glue to accelerate healing of sutures following invasive procedures. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.
Owner:ALLERGAN INC

Remedy for spinal injury containing interleukin-6 antagonist

A therapeutic agent for spinal cord injury, a modulator of differentiation of neural stem cells and an inhibitor of differentiation into glia cells comprising an interleukin-6 antagonist as an active ingredient.
Owner:CHUGAI PHARMA CO LTD +1

Purified populations of stem cells

The invention is directed to a purified population of mammalian endothelial, muscle, or neural stem cells. The invention further provides methods for isolating such populations of cells; methods for using such populations of cells for treating mammals; methods for making vectors for gene therapy; and methods for carrying out gene therapy with such vectors.
Owner:CORNELL RES FOUNDATION INC +2

Nerve Regeneration Promoting Agent

A neuronal differentiation promoting agent for neural stem cells comprising, as an active ingredient, at least one member selected from the group consisting of ω-3 unsaturated fatty acids and ω-6 unsaturated fatty acids having 18 to 22 carbon atoms, and derivatives thereof. The agent can be used for induction of differentiation of neural stem cells and is useful for treating and / or preventing a variety of neurological diseases, and in the fields of nerve transplantation and / or regenerative medicine for nerves.
Owner:MOCHIDA PHARM CO LTD +1

Conditioned cell culture medium compositions and methods of use

InactiveUS7118746B1Eliminate wrinkles, frown lines, scarringCondition the skinOrganic active ingredientsCosmetic preparationsReserve CellCell culture media
Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and / or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, formulated with a salve or ointment for topical applications, or, for example, made into or added to surgical glue to accelerate healing of sutures following invasive procedures. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.
Owner:ALLERGAN INC

Differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene

There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and / or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and / or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention.
Owner:SANBIO

Method for in vitro amplifying, and in 3D solid culturing nerve stem

This invention relates to a method for amplifying neural stem cells in vitro by 3-dimensional culture. The method comprises: selecting microcarrier with 3-dimensional environment, pre-treating, coating the microcarrier with 40-60 ng / mL alkaline fibroblast growth factor, 40-60 ng / mL epidermal growth factor, and B27 DMEM / F12 neural stem cell serum-free culture medium, adding 1X105-1X106 neural stem cells into the culture bottle, taking out the microcarrier grown with neural stem cells, removing the microcarrier, and rinsing cells to obtain neural stem cells. The porous microcarrier can enlarge the culture area. The alkaline fibroblast growth factor and epidermal growth factor can promote cell multiple fission and improve cell microenvironment, which is advantageous for multiple fission of neural stem cells.
Owner:CHINA JAPAN FRIENDSHIP HOSPITAL

Method for differentiating mesenchymal stem cells into neural cells

A method for differentiating mesenchymal stem cells of bone marrow into neural cells comprises culturing the mesenchymal stem cells in a medium containing epidermal growth factor(EGF), basic fibroblast growth factor(bFGF) and hepatocyte growth factor(HGF), and the neural cells produced thereby can be employed for the treatment of a neural disease.
Owner:PHARMICELL +1

Treatment of disease or injury of the nervous system with FTY720

Methods for modulating neurogenesis in vitro and in vivo have been disclosed. The methods comprise contacting neural stem cells with an effective amount of a FTY720 compound. The neurogenesis may involve the modulation of proliferation, differentiation, migration or survival of a non-embryonic neural stem cells or progenitor cells. Also disclosed are methods for the prevention or treatment of neurological disorders comprising administering to a subject a therapeutically effective amount of a FTY720 compound. The disorders that can be treated include various nervous system disorders.
Owner:NEURONOVA AB COMPANY REGISTRATION NO 556703 0118

Cell therapy for chronic stroke

A method of treating stroke in a patient who has undergone a stroke comprising administering at least 2 million suitable neuronal cells to at least one brain area involved in the stroke. The method comprises the step of using a twist drill or a burr to form a hole in the skull through which the cells could be administered. Exemplary cells are hNT neuronal cells, HCN-1 cells, fetal pig cells, neural crest cells, neural stem cells, or a combination thereof. Also disclosed herein is a pharmaceutical composition of 95% pure hNT neuronal cells, which composition further includes a vial containing PBS and human neuronal cells. This vial is provided in a container with liquid nitrogen, whereby the composition is frozen and maintained at -170° C. before use. Also disclosed are methods of improving speech, cognitive, sensory, and motor function in a person who has experienced brain damage which interferes with function by administering a sterile composition of a sufficient number of neuronal cells or neural stem cells to the damaged area. Also disclosed is a method of replacing central nervous cells lost to neurodegenerative disease, trauma, ischemia or poisoning.
Owner:LAYTON BIOSCI +1

Implanting neural progenitor cells derived for human embryonic stem cells

InactiveUS7011828B2Eliminate inhibitory influenceSolve the shortageBiocideNervous disorderNeural cellIn vivo
The present invention relates to undifferentiated human embryonic stem cells, methods of cultivation and propagation and production of differentiated cells. In particular it relates to the production of human ES cells capable of yielding somatic differentiated cells in vitro, as well as committed progenitor cells such as neural progenitor cells capable of giving rise to mature somatic cells including neural cells and / or glial cells and uses thereof.This invention provides methods that generate in vitro and in vivo models of controlled differentiation of ES cells towards the neural lineage. The model, and cells that are generated along the pathway of neural differentiation may be used for: the study of the cellular and molecular biology of human neural development, discovery of genes, growth factors, and differentiation factors that play a role in neural differentiation and regeneration, drug discovery and the development of screening assays for teratogenic, toxic and neuroprotective effects.
Owner:ES CELL INT +1

Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells

InactiveUS20050032702A1Modulate proliferationModulate differentiationNervous disorderPeptide/protein ingredientsOligodendrocytePharmacy medicine
Use of a substance that upon administration will lead to increased concentrations of growth hormone, such as growth hormone, a functionally equivalent analogue thereof or a substance that will increase the release of endogenous growth hormone, for the production of a medicinal product for treatment of abnormal conditions affecting neural stem cells, progenitor cells and / or cells derived from neural stem cells or progenitor cells, especially conditions affecting the oligodendroglia, astroglia, and / or neuronal cells. In vitro and in vivo methods for inducing lineage determination, propagating and / or inducing or maintaining the genesis of neurons, oligodendrocytes, astroglial cells from progenitor cells, stem cells and / or cells derived from said cells by administrating to the cells a substance that increases the concentration of growth hormone. Also a method of reducing the genesis of oligodendrocytes, neurons, astroglial cells from progenitor cells or stem cells, wherein a pharmaceutically effective amount of a substance that will lead to a decreased concentration of growth hormone or a functionally equivalent analogue thereof is administered to said patient.
Owner:ERIKSSON PETER

Antagonists of a non-selective cation channel in neural cells

InactiveUS20100092469A1Reduce mortalityReduces stroke sizeBiocideNervous disorderDiseaseNervous system
The present invention is directed to a combination of therapeutic compounds and treatment methods and kits using the combination. In particular, one of the combination affects the NCca-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system. Exemplary SUR1 and / or TRPM4 antagonists that inhibit the NCca-ATP channel may be employed in the combination. The combination therapy also employs one or more of a non-selective cation channel blocker and / or an antagonist of VEFG, NOS, MMP, or thrombin. Exemplary indications for the combination therapy includes the prevention, diminution, and / or treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury, for example. In other embodiments, there are methods and compositions directed to antagonists of TRPM4, including at least for therapeutic treatment of traumatic brain injury, cerebral ischemia, central nervous system (CNS) damage, peripheral nervous system (PNS) damage, cerebral hypoxia, or edema, for example.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS

Formative agent of protein complex

The present invention proposes formative agent of protein complex, in which a polyphenol is useful component, and the agent is useful as gene complex, cell adhesion inhibitor or immune tolerogen. The polyphenol of forming the agent is selected from catechin group consisting of epigallocatechin-gallate, tannic acids, or proanto-dianisidine, a protein of the protein complex is selected from proteins consisting of animal proteins composed of polypeptide chain of peptide-combined amino acids, vegetative proteins, nucleus proteins, glycogen proteins, lipo-proteins and metal proteins, the gene complex comprises by compositing genes by polyphenol catechins in order to introduce genes to cells of animals or human bodies, a cell composed of the cell adhesion inhibitor is selected from cells consisting of an animal cell including a stem cell, skin cell, mucosa cell, hepatocyte, islet cell, neural cell, cartilage cell, endothelial cell, epidermal cell, osteocyte or muscle cell isolated from human or animal organism, or sperm, ovum or fertilized egg of domestic animals or fishes and a tissue or an organ for transplantation of the immune tolerogen is selected from the tissue or the organ consisting of skin, blood vessel, cornea, kidney, heart, liver, umbilical cord, bowels, nerve, lung, placenta or pancreas.
Owner:BERTELSMANN MUSIC GROUP

Cryopreservation and resuscitation method of neural stem cells

The invention provides a cryopreservation method and a resuscitation method of neural stem cells (NSCs), and provides a cryopreserved NSC solution and a resuscitated NSC solution with cell survival rates higher than 90%. The solutions are prepared with the methods provided by the invention. Also, the invention provides a cryopreservation medium and a resuscitation medium used in the NSC cryopreservation method and resuscitation method.
Owner:SHANGHAI ANGECON BIOTECH

Method for inducing transdifferentiation of somatic cells into neural stem cells and application thereof

ActiveCN104894060AGood pluripotent differentiation performanceNervous disorderNervous system cellsDiseaseTransdifferentiation
Provided are a method for inducing the transdifferentiation of somatic cells into neural stem cells and application for same. Using a combination of a histone deacetylase (HDAC) inhibitor, a glycogen synthase kinase (GSK-3) inhibitor, and a transforming growth factor β (TGF-β) signal pathway inhibitor, in a low-oxygen normal physiological environment, induce somatic cells such as fibroblasts and epithelial cells to form into neural stem cells having good pluripotency and passage stability.
Owner:CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI

Method for constructing three-dimensional neural stem cell model in two steps by adopting micro-fluidic technology

The invention relates to a method for constructing a three-dimensional neural stem cell model in two steps by adopting the micro-fluidic technology. The method is characterized in that a rat tail collagen I is used as a three-dimensional support, a micro-pillar array type micro-fluidic chip is used as a culture platform, and a neural stem cell is cultured in two steps, wherein in the early culture stage, a culture medium for promoting the amplification of the neural stem cell is injected into a cell culture chamber, and in the later culture stage, a conditioned medium suitable for the growth of the neural stem cell and the daughter cells thereof is used, and a three-dimensional composite structure which is similar to a nerve tissue is formed by simulating the microenvironment of different neurogenesis stages in the body. The method provided by the invention is good in repeatability and can be used for construction a plurality of groups of samples. The adopted microfluidic culture system is in a microliter volume and can be regulated accurately, thus the amount of various high-cost cell growth factors, immunologic fluorescent antibodies and cell hormones used in the process of culturing the cell can be reduced greatly, and the cell culture cost can be lowered. The three-dimensional neural stem cell model is expected to be a nerve tissue substitute for screening a novel medicament or monitoring an environmental toxin.
Owner:DALIAN UNIV OF TECH

Culture medium for preparing neural stem cells and application thereof

The invention relates to a culture medium for preparing neural stem cells and an application of the culture medium. The culture medium for preparing the neural stem cells comprises a culture medium suitable for the growth of stem cells, and a cell signal pathway inhibitor which is selected from at least one of the following agents: a GSK (Glaxo Smith Klein) inhibitor, an MEK (Methyl Ethyl Ketone) inhibitor, a TGF (Transforming Growth Factor)-beta inhibitor, a ROCK inhibitor and a BMP inhibitor. The somatic cells are cultured by using the culture medium, especially the somatic cells for expressing the transcription regulator are cultured, so as to effectively transdifferentiate the somatic cells into neutral stem cells and the transdifferentiation time is greatly shortened.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI

Bioactive peptides and unique ires elements from myelin proteolipid protein plp/dm20

Three novel low molecular weight (LMW) polypeptide fragments of a proteolipid protein human PLP / DM20 are designated PIRP-M, PIRP-L and PIRP-J, and are growth factors for oligodendrocytes with anti-apoptotic activity. They are encoded by mRNA from an IRES. Fusion polypeptides of such a LMW polypeptide, DNA encoding the LMW polypeptide and fusion polypeptide, expression vectors comprising such DNA, and cells expressing such polypeptides, or pharmaceutical compositions thereof, are useful for stimulating neural stem cell differentiation, maturation along the oligodendrocytic pathway and proliferation of oligodendrocytes or precursors. These compositions can protect oligodendrocytes (and nonneural cells) from apoptotic death. Thus, the present composition is used to treat a disease or condition in which such differentiation, maturation and proliferation or inhibition of cell death, including remyelination or stimulation of oligodendroglia or Schwann cells, is desirable. Disorders include multiple sclerosis, trauma with Parkinson's-like symptoms, hypoxic ischerriia and spinal cord trauma.
Owner:WAYNE STATE UNIV

Stem cell therapy for the treatment of central nervous system disorders

The invention provides a method for treating CNS disorders by administering a neural stem cell composition and a mesenchymal stem cell composition on opposing sides of the blood brain barrier. The neural stem cell composition is administered to the central nervous system, while the mesenchymal stem cell composition is administered to the circulatory system, such as by intravenous injection. The method finds use in the treatment of degenerative GNS disorders, as well as traumatic CNS disorders such as stroke and spinal cord injury.
Owner:MIRONOV NIKOLAY

Combined regulation of neural cell production

This invention relates to a method of selectively producing neural cells, including neurons or glial cells, in vitro or in vivo. Also provided are methods of treating or ameliorating neurodegenerative disease or medical conditions by producing neural cells. Thus, a combination of factors is used to achieve two steps: increasing the number of neural stem cells and instructing the neural stem cells to selectively become neurons or glial cells.
Owner:STEM CELL THERAPEUTICS

Chemical inducers of neurogenesis

InactiveUS20090036451A1Promotes and enhances well-beingReduce frequencyBiocideNervous disorderNervous systemNeurogenesis
The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in the treatment of neurodegenerative and psychiatric diseases, the repair and regeneration of the nervous system, and in treatment of neurologic malignancy.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Modulation of beta-catenin coactivator interactions to effect stem cell growth or differentiation

Methods and agents are disclosed for modulating the interaction of β-catenin or γ-catenin with CBP or p300. Agents that increase the binding of CBP to β-catenin are associated with enhancing the β-catenin-related proliferation of adult stem cells, including hematopoietic stem cells, neural stem cells, skin stem cells, and pancreatic stem cells.
Owner:JW PHARMA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products